Covered recipient · General Payments record
ALEXIS K WARREN
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2018–2024
$7,946.08
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $3,620.00 | 2 |
| Food and Beverage | $795.62 | 7 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $3,751.38 | 3 |
| ABBVIE INC. | $267.92 | 3 |
| Alcon Laboratories Inc | $145.73 | 1 |
| EyePoint Pharmaceuticals US, Inc. | $137.59 | 1 |
| Genentech USA, Inc. | $113.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $124.36 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106309999 | CMS |
| ABBVIE INC. | $111.02 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106310001 | CMS |
| ABBVIE INC. | $32.54 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106310003 | CMS |
| Alcon Vision LLC | $145.73 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110693967 | CMS |
| EyePoint Pharmaceuticals US, Inc. | $137.59 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089507146 | CMS |
| Genentech USA, Inc. | $113.00 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132974027 | CMS |
| Regeneron Pharmaceuticals, Inc. | $131.38 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114406415 | CMS |
| Regeneron Pharmaceuticals, Inc. | $1,448.00 | 12/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114406417 | CMS |
| Regeneron Pharmaceuticals, Inc. | $2,172.00 | 12/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1114406419 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.